Business Context and Reporting Period
This Form 8-K Current Report was filed by Neogen Corporation on July 24, 2025. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Executive Officer and Item 8.01 regarding the issuance of a related press release.
Key Financial Metrics
This filing does not contain operational financial results such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the executive compensation package for the incoming CEO:
- Base Salary: $800,000 annually.
- Target Annual Bonus: 100% of base salary ($800,000), with a potential range of 0% to 250%.
- Long-Term Incentive Target: $4,500,000 in equity value at grant.
- Sign-On Equity Grant: $2,000,000 (50% stock options, 50% RSUs) vesting over four years.
- Sign-On Cash Award: $500,000, payable by September 5, 2025, subject to clawback if employment terminates within one year.
Material Changes
The material change reported is the appointment of Mikhael Nassif as President and Chief Executive Officer, effective August 11, 2025. Mr. Nassif joins from Siemens Healthineers, where he served as Global President of Point-of-Care Diagnostics. He brings prior leadership experience from Baxter International, Anheuser-Busch InBev, and Johnson & Johnson.
Outlook, Risks, and Contingencies
Management Commentary: The Board of Directors approved the appointment and the associated compensatory arrangements. Mr. Nassif is eligible for the full year of the Incentive Compensation Plan for Fiscal Year 2026 (June 1, 2025, through May 31, 2026) without proration.
Contingencies and Repayment Obligations:
- Sign-On Cash: Must be repaid if employment terminates within one year.
- Relocation Benefits: Mr. Nassif will relocate to Michigan after 24 months of service. Benefits include realtor fees, moving expenses, house hunting trips, and a furnished apartment for the first 24 months. Repayment terms are 100% if he terminates within one year of relocating and 50% if he terminates within two years of relocating.
- Termination Benefits: Consistent with other senior executives, including severance upon qualifying termination or change in control.
Investor Verification Checklist
- Verify the effective start date of August 11, 2025, for Mikhael Nassif.
- Review the attached Offer Letter (Exhibit 10.1) for full terms of the compensation package and termination provisions.
- Confirm the vesting schedule details for the $2,000,000 sign-on equity grant.
- Monitor future filings for the transition of the previous CEO and any impact on strategic direction.